EGFR and non-small cell lung carcinoma: Mechanistically, in non-small cell lung cancer, mutations in EGFR lead to destabilization of the nonactive conformation of the EGFR protein and continuous activation of its kinase domain (Di Maio, 2023), which leads to continuous autophosphorylation of the C-terminal tyrosine site and results in tumorigenesis (Irmer et al., 2007; Reita et al., 2021).